Usefulness of hypoxia inducible factor-1 alpha in evaluating the prostatic adenocarcinoma viability following neoadjuvant hormone therapy

Kimbro, 2006, Hypoxia-inducible factor-1 in human breast and prostate cancer, Endocr Relat Cancer, 13, 739, 10.1677/erc.1.00728 Semenza, 2002, HIF-1 and tumor progression: pathophysiology and therapeutics, Trend Mol Med, 8, 62, 10.1016/S1471-4914(02)02317-1 Huang, 1998, Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway, Proc Natl Acad Sci U.S.A., 95, 7987, 10.1073/pnas.95.14.7987 Jiang, 1996, Hypoxia-inducible factor 1 levels vary exponentially over a physiologically range of O2 tension, Am J Physiol, 271, 1172, 10.1152/ajpcell.1996.271.4.C1172 Maxwell, 1999, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, Nature, 399, 271, 10.1038/20459 Zhong, 2004, Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis, Cancer Detect Prev, 28, 88, 10.1016/j.cdp.2003.12.009 Hudson, 2002, Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin, Mol Cell Biol, 22, 7004, 10.1128/MCB.22.20.7004-7014.2002 Madjeesh, 2002, Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells, Cancer Res, 62, 2478 Mabjeesh, 2003, Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells, Clin Cancer Res, 9, 2416 Palayoor, 2003, Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells, Clin Cancer Res, 9, 3150 Thomas, 2005, Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells, Biochem Biophys Res Commun, 334, 543, 10.1016/j.bbrc.2005.06.114 Tokunaga, 2005, Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer, Oncol Rep, 13, 1081 Kyprianou, 1990, Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation, Cancer Res, 50, 3748 Cookson, 1997, Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study, Br J Urol, 79, 432, 10.1046/j.1464-410X.1997.00022.x Fair, 1997, The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results, Urology, 49, 46, 10.1016/S0090-4295(97)00169-6 Klotz, 1999, CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results, Urology, 53, 757, 10.1016/S0090-4295(98)00616-5 Soloway, 1995, Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer, J Urol, 154, 424, 10.1016/S0022-5347(01)67067-8 Labrie, 1994, Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinzing hormone-releasing hormone agonist, Urology, 44, 29, 10.1016/S0090-4295(94)80241-6 Kitagawa, 2003, Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy, Int J Urol, 10, 377, 10.1046/j.1442-2042.2003.00640.x Zhong, 1999, Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases, Cancer Res, 59, 5830 Du, 2003, Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue, Chin Med J, 116, 1936 Zhong, 2000, Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostatic cancer cells: implications for tumor angiogenesis and therapeutics, Cancer Res, 60, 1541 Tan, 2005, Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway, Cancer Res, 65, 605, 10.1158/0008-5472.605.65.2